Konety B R, Lavelle J P, Pirtskalaishvili G, Dhir R, Meyers S A, Nguyen T S, Hershberger P, Shurin M R, Johnson C S, Trump D L, Zeidel M L, Getzenberg R H
Departments of Urology, Surgery, Medicine, Pathology and Pharmacology, University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
J Urol. 2001 Jan;165(1):253-8. doi: 10.1097/00005392-200101000-00074.
Vitamin D (calcitriol) has significant antiproliferative effects on various tumor cells in vitro and in vivo. In the clinical situation a major impediment to systemic administration of calcitriol is the side effect of hypercalcemia. To test the potential usefulness of calcitriol for bladder cancer treatment, we studied the antiproliferative effect of vitamin D on 2 human bladder cancer cell lines, 253j and T-24, in vitro. We also examined the in vivo effects of calcitriol in an animal model of bladder cancer using intravesical administration to avoid the toxicity of systemic calcitriol therapy.
The presence of vitamin D receptors in normal and neoplastic human bladder tissue, and tumor cells T-24 and 253j was determined by immunoblot analysis. Tumor cell proliferation in the presence or absence of calcitriol was determined using a crystal violet assay. Calcitriol induced apoptosis was determined by morphology, polyadenosine diphosphate ribose polymerase cleavage and annexin V binding. In vivo studies were performed by weekly intravesical instillation of calcitriol in female Fischer 344 rats after induction of tumors by N-methyl nitrosourea. Calcitriol administration was started 3 weeks after tumor induction for 7 doses at weekly intervals.
Normal and neoplastic human bladder tissue, and the cell lines expressed vitamin D receptors. In the 253j and T-24 cell lines proliferation was significantly inhibited by calcitriol. Progressive cleavage of full length polyadenosine diphosphate ribose polymerase was observed in calcitriol treated cells starting as early as 4 hours after exposure. Similar changes were not observed in the control cells treated with vehicle (ethanol) alone. After 24 hours of treatment with calcitriol 45.8% of 253j cells bound annexin compared to 16.5% of control cells (chi-square p <0.001). Of the control animals 66% developed bladder tumors and 55% of the animals treated with calcitriol early (3 weeks) after tumor induction developed bladder tumors. Almost all of the tumors that developed in the calcitriol group were unifocal, and only 20% were invasive compared to 50% of those in the control animals.
These results demonstrate that calcitriol inhibits proliferation and induces apoptosis in human bladder tumor cells in vitro, and may have therapeutic potential in bladder cancer. In vivo studies using an N-methylnitrosourea induced model of bladder cancer demonstrate that early institution of intravesical calcitriol therapy after carcinogen exposure results in fewer tumors, which are also less likely to be multifocal, high grade or invasive. With our protocol a short course of intravesical calcitriol administration did not result in any significant toxicity.
维生素D(骨化三醇)在体外和体内对多种肿瘤细胞具有显著的抗增殖作用。在临床情况下,骨化三醇全身给药的主要障碍是高钙血症的副作用。为了测试骨化三醇对膀胱癌治疗的潜在效用,我们在体外研究了维生素D对两种人膀胱癌细胞系253j和T-24的抗增殖作用。我们还通过膀胱内给药在膀胱癌动物模型中研究了骨化三醇的体内作用,以避免全身骨化三醇治疗的毒性。
通过免疫印迹分析确定正常和肿瘤性人膀胱组织以及肿瘤细胞T-24和253j中维生素D受体的存在。使用结晶紫测定法确定在有或没有骨化三醇存在的情况下肿瘤细胞的增殖。通过形态学、聚腺苷二磷酸核糖聚合酶裂解和膜联蛋白V结合来确定骨化三醇诱导的细胞凋亡。在通过N-甲基亚硝基脲诱导肿瘤后,对雌性Fischer 344大鼠每周进行一次膀胱内滴注骨化三醇进行体内研究。在肿瘤诱导后3周开始给予骨化三醇,每周一次,共7剂。
正常和肿瘤性人膀胱组织以及细胞系均表达维生素D受体。在253j和T-24细胞系中,骨化三醇显著抑制增殖。早在暴露后4小时,在骨化三醇处理的细胞中就观察到全长聚腺苷二磷酸核糖聚合酶的逐步裂解。在用载体(乙醇)单独处理的对照细胞中未观察到类似变化。用骨化三醇处理24小时后,253j细胞中有45.8%结合膜联蛋白,而对照细胞为16.5%(卡方检验p<0.001)。在对照动物中,66%发生了膀胱肿瘤,而在肿瘤诱导后早期(3周)用骨化三醇处理的动物中有55%发生了膀胱肿瘤。骨化三醇组中几乎所有发生的肿瘤都是单灶性的,只有20%是浸润性的,而对照动物中这一比例为50%。
这些结果表明,骨化三醇在体外可抑制人膀胱肿瘤细胞的增殖并诱导其凋亡,在膀胱癌中可能具有治疗潜力。使用N-甲基亚硝基脲诱导的膀胱癌模型进行的体内研究表明,在接触致癌物后早期进行膀胱内骨化三醇治疗可减少肿瘤数量,这些肿瘤也不太可能是多灶性、高级别或浸润性的。按照我们的方案,短期膀胱内给予骨化三醇不会导致任何明显的毒性。